Diagnostic Approaches for Pancreatic Islet Cell Tumors

Initial Evaluation

The National Comprehensive Cancer Network recommends obtaining a family history to rule out Multiple Endocrine Neoplasia type 1 (MEN 1) syndromes, as islet cell tumors occurring in MEN 1 patients are typically multiple and require different treatment strategies 1
Pancreatic neuroendocrine tumors (islet cell tumors) account for approximately 1% of pancreatic cancers by incidence and 10% by prevalence 1
40-91% of pancreatic neuroendocrine tumors are nonfunctional, while the remainder manifest with clinically evident hormonal symptoms 2

The National Comprehensive Cancer Network recommends multiphasic, contrast-enhanced CT or MRI as the initial imaging modality for both functioning and non-functioning islet cell tumors 1, 2
MRI is preferred over CT for follow-up due to better soft tissue contrast and avoidance of radiation exposure, especially important since patients may require lifelong imaging 3
MRI is more sensitive than CT for depicting small liver metastases, identifying metastases not visible on CT in 10-23% of cases 4
CT should be performed according to a defined pancreas protocol with triphasic cross-sectional imaging and thin slices (3mm) 5
Optimal multi-phase technique includes non-contrast phase, arterial phase, pancreatic parenchymal phase, and portal venous phase 5, 6
MRI sequences should include fat-suppressed T1-weighted sequences, diffusion-weighted sequences, magnetic resonance cholangiopancreatography (MRCP), and multiphasic contrast-enhanced sequences 3, 4, 6

EUS is complementary to CT/MRI for staging and is particularly valuable for small tumors (<2cm) that may be missed on CT/MRI, isodense tumors on CT, and assessment of vascular involvement 1, 4, 5
EUS-guided fine needle aspiration (FNA) is preferred over CT-guided FNA for tissue diagnosis due to better diagnostic yield, greater safety, and lower risk of peritoneal seeding 5, 7

For nonfunctioning islet cell tumors, multiphasic CT or MRI scan is the primary diagnostic tool, and serum chromogranin A testing may be considered (elevated in 60% or more of patients) 1, 2
For functioning islet cell tumors, such as insulinomas, EUS is particularly valuable, with reported sensitivity of 70-85%, and calcium stimulation test (Imamura-Doppman procedure) may be considered for persistent or recurrent insulinoma or when other localization tests are equivocal 1
For gastrinomas, measurement of basal and stimulated gastrin levels is essential, and imaging studies (multiphasic CT/MRI) aid in both localizing the tumor and confirming diagnosis 1, 2

Chromogranin A levels should be interpreted with caution as false elevations occur in patients using proton pump inhibitors, those with renal or liver failure, hypertension, or chronic gastritis 1, 2
Octreoscan (somatostatin receptor scintigraphy) can be considered as a complementary imaging modality, particularly for functional tumors 1
PET-CT is not routinely recommended for initial diagnosis due to overlap with findings in autoimmune and chronic pancreatitis 4